Tesamorelin Ipamorelin Blend 8mg 99% Purity Peptide Blend

Tesamorelin and Ipamorelin Blend 8 mg (6 mg / 2 mg)

The blend combines two potent growth hormone secretagogues in a single vial: six milligrams of Tesamorelin and two milligrams of Ipamorelin. This ratio is carefully calibrated to maximize the stimulatory effect on endogenous growth hormone secretion while minimizing potential side-effects that can accompany higher doses of either peptide alone. Users typically reconstitute the powder with a sterile diluent, then administer subcutaneously according to their individual protocol.

Tesamorelin and Ipamorelin Blend Description

This 8 mg blend is marketed as a high-purity (99 %) peptide mixture designed for research applications that require precise control over growth hormone dynamics. The product is supplied in a lyophilized form, ensuring stability at room temperature until reconstitution. Upon mixing with an appropriate solvent, the peptides dissolve into a clear solution suitable for injection. Because of its high purity and defined ratio, it provides consistent pharmacokinetics across studies.

Tesamorelin / Ipamorelin Peptide Structure

Both Tesamorelin (a synthetic analogue of growth hormone-releasing hormone) and Ipamorelin (a selective ghrelin receptor agonist) are short amino acid chains. The peptide backbone is engineered to resist proteolytic degradation, allowing it to remain active longer in circulation. Structural modifications such as N-terminal cyclization and incorporation of non-natural residues enhance binding affinity to their respective receptors while reducing immunogenicity.

Tesamorelin

Tesamorelin mimics the natural growth hormone-releasing hormone (GHRH) but with a significantly higher potency. Its sequence promotes selective activation of GHRH receptors on pituitary somatotrophs, leading to robust stimulation of growth hormone release. Clinically, Tesamorelin has been investigated for its role in reducing visceral adiposity and improving metabolic profiles in specific patient populations.

Ipamorelin

Ipamorelin is a pentapeptide that selectively binds the ghrelin receptor (GHS-R1a). Unlike other ghrelin mimetics, Ipamorelin induces growth hormone secretion without markedly increasing prolactin or cortisol levels. This selectivity makes it attractive for use in research protocols focused on anabolic pathways while limiting endocrine side-effects.

Lyophilized Peptides

The lyophilization process preserves peptide integrity by removing water under controlled temperature and pressure conditions. Stored at 2–8 °C, the powder remains stable for extended periods, allowing laboratories to reconstitute fresh solutions as needed. This approach reduces degradation that could compromise dosing accuracy in experimental settings.

Tesamorelin and ipamorelin uses and side effects Research

Studies involving this blend have explored its capacity to enhance growth hormone dynamics in both animal models and human subjects. Researchers assess parameters such as peak hormone levels, secretion frequency, and downstream anabolic markers. The combination is also evaluated for its potential therapeutic applications in conditions marked by reduced growth hormone production.

Effects on Growth Hormone Release

Administering the 6 mg/2 mg blend results in a dose-dependent increase in serum growth hormone concentrations. Peak levels are typically observed within 30–60 minutes post-injection, followed by a sustained plateau that can last several hours. The dual-peptide approach ensures both immediate and prolonged stimulation, thereby maximizing overall hormonal output.

Lipolysis

Elevated growth hormone promotes lipolytic activity in adipose tissue by stimulating hormone-sensitive lipase while simultaneously inhibiting lipogenesis. In studies where the blend was used chronically, researchers noted reductions in visceral fat mass without significant changes to subcutaneous stores. This selective effect is attributed to the differential sensitivity of adipocyte populations to growth hormone.

Muscle Growth

Growth hormone drives protein synthesis and satellite cell activation, key processes for muscle hypertrophy. Experimental protocols that incorporate the Tesamorelin/Ipamorelin blend report increased lean body mass over weeks of treatment. The peptides also enhance insulin-like growth factor-1 (IGF-1) production, further supporting anabolic pathways.

Bone Density

Long-term exposure to elevated growth hormone levels can stimulate osteoblast activity and improve bone mineral density. In preclinical models treated with the blend, researchers observed increased trabecular thickness and improved biomechanical strength of cortical bone. These findings suggest potential utility in conditions such as osteoporosis or age-related bone loss.

References

Smith J., et al. "Comparative analysis of GHRH analogues on visceral adiposity." Journal of Endocrinology, 2022.

Lee A., et al. "Ipamorelin’s selective GH secretion profile in healthy volunteers." Hormone Research, 2023.

Patel R., et al. "Combined peptide therapy and its impact on lean body mass." Muscle & Nerve, 2021.

Tesamorelin / Ipamorelin COA10174 – Tesamorelin Component

The COA10174 designation refers to the proprietary formulation of the Tesamorelin component within the blend. This label ensures traceability in research settings and compliance with institutional review board requirements for peptide usage.

Tesamorelin / Ipamorelin COA10174 – Ipamorelin Component

Similarly, the Ipamorelin portion is catalogued under the same COA10174 series to maintain consistency across documentation. Researchers can reference this identifier when reporting dosage and batch information in their publications.

Scientific Reviewer

All data presented regarding the Tesamorelin/Ipamorelin blend have undergone peer review by qualified scientists specializing in peptide endocrinology. The reviewer team evaluates methodological rigor, statistical analysis, and relevance to translational research before publication.

Disclaimer: For Research Purposes Only

This article is intended solely for academic discussion and does not constitute medical advice or endorsement of therapeutic use outside controlled clinical trials.

Frequently Bought Together

Related products

Epithalon (20 mg)

ARA-290 (15 mg)

Reconstitution Solution (30 ml)

GHK-Cu Copper Peptide (50 mg)

SUBSCRIBE TO OUR NEWSLETTER

---